BN104 as maintenance therapy after stem cell transplant for leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called BN104 to help keep leukemia from coming back after a stem cell transplant. It's for people with certain types of acute leukemia that have specific gene changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older and weigh at least 77 pounds (35 kg).
- You have a type of acute leukemia (AML, ALL, or mixed) that is intermediate or high risk.
- You have a specific gene change in your leukemia cells (like NPM1, KMT2A, or NUP98).
- You have had a donor stem cell transplant 30 to 180 days ago, and you are in complete remission now.
- Your blood counts have recovered (ANC ≥ 1.0, platelets ≥ 75) without needing transfusions or growth factors for at least 7 days.
- You are not taking other maintenance therapies for your leukemia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how well a newer drug class (menin inhibitors) works to prevent acute leukemia from coming back after a stem cell transplant. You would be observed for safety and effectiveness if you're already taking one of these drugs.
This clinical trial tests a new menin-blocking drug called BN104 in combination with chemotherapy or other targeted drugs for people with acute myeloid leukemia (AML) that has certain genetic changes. It may be an option if your AML is newly diagnosed or if you've already tried a menin inhibitor and it didn't work well enough.
This trial tests different maintenance therapies based on the specific gene mutations in your leukemia or MDS after a stem cell transplant. Your doctor will choose the right drug for your mutation type to help keep the cancer from coming back.
This trial tests whether three targeted medicines (decitabine, venetoclax, and blinatumomab) can help prevent leukemia from coming back after a stem cell transplant. It is for people with B-cell ALL who have no detectable remaining leukemia cells and are at least 3 months past transplant.
This trial tests a pill called avapritinib to keep leukemia from coming back after a stem cell transplant. It is for people with AML that has a KIT mutation.
This trial tests a combination of two drugs (SHR2554 and azacitidine) given before a stem cell transplant for people with high-risk or relapsed leukemia or MDS. The goal is to see if this approach can help make the transplant more effective and reduce the chance of the disease coming back.
Hear when a new Maintenance Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.